Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
ATFB
MCID: FML001
MIFTS: 65

Familial Atrial Fibrillation (ATFB)

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Rare diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Familial Atrial Fibrillation

About this section

MalaCards integrated aliases for Familial Atrial Fibrillation:

Name: Familial Atrial Fibrillation 12 52 25 58 29 6 15 71
Atrial Fibrillation, Familial 52 25 54
Atfb 12 52
Atrial Fibrillation Autosomal Dominant 52
Autosomal Dominant Atrial Fibrillation 52
Atrial Fibrillation, Familial, 1 71
Auricular Fibrillation 25
Atrial Fibrillation 71

Characteristics:

Orphanet epidemiological data:

58
familial atrial fibrillation
Inheritance: Autosomal dominant;

Classifications:

MalaCards categories:
Global: Rare diseases Genetic diseases
Anatomical: Cardiovascular diseases Respiratory diseases Blood diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0050650
ICD10 via Orphanet 33 I48.9
Orphanet 58 ORPHA334
UMLS 71 C0004238 C1843687 C3468561
Sources

Summaries for Familial Atrial Fibrillation

About this section
NIH Rare Diseases : 52 Familial atrial fibrillation is an inherited heart condition that disrupts the heart's rhythm. It is characterized by erratic electrical activity in the heart's upper chambers (the atria), causing an irregular response in the heart's lower chambers (the ventricles). This causes a fast and irregular heartbeat (arrhythmia ). Signs and symptoms may include dizziness, chest pain, palpitations , shortness of breath, or fainting. Affected people also have an increased risk of stroke and sudden death. While complications may occur at any age, some affected people never have associated health problems. Familial atrial fibrillation may be caused by changes (mutations ) in any of various genes , some of which have not been identified. It is most often inherited in an autosomal dominant manner, but autosomal recessive inheritance has been reported.

MalaCards based summary : Familial Atrial Fibrillation, also known as atrial fibrillation, familial, is related to atrial fibrillation and cardiac arrhythmia, and has symptoms including edema, chest pain and angina pectoris. An important gene associated with Familial Atrial Fibrillation is MYL4 (Myosin Light Chain 4), and among its related pathways/superpathways are Cardiac conduction and cGMP-PKG signaling pathway. The drugs Irbesartan and carbamide peroxide have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and brain, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 An atrial fibrillation that has material basis in autosomal dominant inheritance of the familial atrial fibrillation (ATFB) genes.

Genetics Home Reference : 25 Familial atrial fibrillation is an inherited abnormality of the heart's normal rhythm. Atrial fibrillation is characterized by episodes of uncoordinated electrical activity (fibrillation) in the heart's upper chambers (the atria), which cause a fast and irregular heartbeat. If untreated, this abnormal heart rhythm (arrhythmia) can lead to dizziness, chest pain, a sensation of fluttering or pounding in the chest (palpitations), shortness of breath, or fainting (syncope). Atrial fibrillation also increases the risk of stroke and sudden death. Complications of atrial fibrillation can occur at any age, although some people with this heart condition never experience any health problems associated with the disorder.

Sources

Related Diseases for Familial Atrial Fibrillation

About this section

Diseases in the Atrial Fibrillation family:

Atrial Fibrillation, Familial, 3 Atrial Fibrillation, Familial, 1
Atrial Fibrillation, Familial, 2 Atrial Fibrillation, Familial, 4
Atrial Fibrillation, Familial, 5 Atrial Fibrillation, Familial, 6
Atrial Fibrillation, Familial, 7 Atrial Fibrillation, Familial, 8
Atrial Fibrillation, Familial, 9 Atrial Fibrillation, Familial, 10
Atrial Fibrillation, Familial, 11 Atrial Fibrillation, Familial, 12
Atrial Fibrillation, Familial, 13 Atrial Fibrillation, Familial, 14
Atrial Fibrillation, Familial, 15 Atrial Fibrillation, Familial, 18
Familial Atrial Fibrillation

Diseases related to Familial Atrial Fibrillation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 175)
# Related Disease Score Top Affiliating Genes
1 atrial fibrillation 32.1 SCN5A SCN4B SCN3B SCN2B PITX2 NUP155
2 cardiac arrhythmia 31.8 SCN5A KCNQ1 KCNJ2 KCNE2
3 heart disease 31.6 SCN5A PITX2 NPPA NKX2-5 KCNQ1 KCNJ2
4 long qt syndrome 31.5 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2 KCNA5
5 congestive heart failure 31.5 SCN5A NPPA KCNQ1 KCNJ2 KCNE2 GJA5
6 ventricular fibrillation, paroxysmal familial, 1 31.4 SCN5A NKX2-5 KCNQ1 KCNE2
7 sick sinus syndrome 31.3 SCN5A SCN3B NPPA KCNQ1 KCNJ2 GJA5
8 atrioventricular block 31.2 SCN5A NKX2-5 KCNQ1 KCNE2 GJA5 GATA4
9 sinoatrial node disease 31.2 SCN5A SCN3B NKX2-5 KCNQ1 KCNJ2 KCNE2
10 long qt syndrome 10 31.0 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
11 familial long qt syndrome 31.0 SCN5A KCNQ1 KCNJ2 KCNE2
12 heart septal defect 31.0 PITX2 NPPA NKX2-5 GJA5 GATA6 GATA5
13 jervell and lange-nielsen syndrome 1 31.0 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
14 wolff-parkinson-white syndrome 31.0 SCN5A NKX2-5 KCNQ1 KCNJ2 KCNE2 GJA5
15 atrial heart septal defect 31.0 SCN5A PITX2 NPPA NKX2-5 GJA5 GATA6
16 short qt syndrome 31.0 SCN5A SCN4B SCN3B KCNQ1 KCNJ2 KCNE2
17 syncope 30.9 SCN5A NPPA KCNQ1
18 long qt syndrome 1 30.9 SCN5A SCN4B SCN3B SCN2B NKX2-5 KCNQ1
19 brugada syndrome 30.9 SCN5A SCN4B SCN3B SCN2B NUP155 NKX2-5
20 dilated cardiomyopathy 30.9 SCN5A SCN4B SCN2B NPPA NKX2-5 KCNQ1
21 atrial fibrillation, familial, 1 30.9 PITX2 ATFB1
22 patent ductus arteriosus 1 30.8 NKX2-5 GATA6 GATA4
23 progressive familial heart block, type ia 30.7 SCN5A GJA5
24 cardiac conduction defect 30.7 SCN5A KCNQ1
25 atrial fibrillation, familial, 15 12.8
26 brugada syndrome 7 12.2
27 atrial fibrillation, familial, 11 11.7
28 atrial fibrillation, familial, 12 11.7
29 atrial fibrillation, familial, 13 11.7
30 atrial fibrillation, familial, 14 11.7
31 myasthenic syndrome, congenital, 5 10.8 SCN5A KCNQ1 KCNJ2 KCNE2 KCNA5 GJA5
32 long qt syndrome 13 10.8 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
33 long qt syndrome 12 10.8 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
34 long qt syndrome 6 10.8 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
35 long qt syndrome 5 10.8 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
36 long qt syndrome 9 10.8 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
37 heart conduction disease 10.8 SCN5A SCN3B KCNQ1 KCNJ2 KCNE2 KCNA5
38 long qt syndrome 3 10.8 SCN5A SCN4B SCN3B KCNQ1 KCNJ2 KCNE2
39 long qt syndrome 11 10.8 SCN4B KCNQ1 KCNJ2 KCNE2
40 long qt syndrome 2 10.8 SCN5A SCN4B SCN3B KCNQ1 KCNJ2 KCNE2
41 cardiac arrhythmia, ankyrin-b-related 10.8 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
42 andersen cardiodysrhythmic periodic paralysis 10.8 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
43 catecholaminergic polymorphic ventricular tachycardia 10.8 SCN5A SCN4B SCN3B KCNQ1 KCNJ2 KCNE2
44 long qt syndrome 14 10.8 SCN5A KCNQ1 KCNJ2
45 timothy syndrome 10.8 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
46 brugada syndrome 4 10.8 SCN5A KCNQ1 KCNJ2
47 intrinsic cardiomyopathy 10.8 SCN5A SCN4B NPPA NKX2-5 KCNQ1 KCNJ2
48 atrial standstill 10.8 SCN5A NPPA GJA5
49 progressive familial heart block 10.8 SCN5A NKX2-5 KCNQ1 GJA5
50 third-degree atrioventricular block 10.8 SCN5A KCNJ2 GJA5

Comorbidity relations with Familial Atrial Fibrillation via Phenotypic Disease Network (PDN): (show top 50) (show all 169)


Accessory Nerve Disease Acquired Polycythemia
Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Conjunctivitis Acute Cor Pulmonale
Acute Cystitis Acute Kidney Failure
Acute Myocardial Infarction Acute Vascular Insufficiency of Intestine
Alcoholic Cardiomyopathy Alcoholic Liver Cirrhosis
Amyloidosis Anemia, Autoimmune Hemolytic
Anthracosis Anxiety
Aortic Aneurysm Aortic Atherosclerosis
Aortic Valve Disease 1 Aortic Valve Disease 2
Aortic Valve Insufficiency Asbestosis
Asthma Atrial Tachyarrhythmia with Short Pr Interval
Atrioventricular Block Bacteremia 2
Basilar Artery Insufficiency Benign Essential Hypertension
Bleeding Disorder, Platelet-Type, 11 Blepharitis
Bronchiectasis Bronchitis
Bronchopneumonia Candidiasis
Cardiac Arrest Cardiac Arrhythmia
Cardiogenic Shock Cerebral Atherosclerosis
Cerebral Degeneration Cerebrovascular Disease
Cholangitis Cholecystitis
Chronic Intestinal Vascular Insufficiency Chronic Pulmonary Heart Disease
Chronic Rheumatic Pericarditis Chronic Ulcer of Skin
Colorectal Cancer Conjunctivitis
Constrictive Pericarditis Coronary Artery Aneurysm

Graphical network of the top 20 diseases related to Familial Atrial Fibrillation:



Diseases related to Familial Atrial Fibrillation
Sources

Symptoms & Phenotypes for Familial Atrial Fibrillation

About this section

UMLS symptoms related to Familial Atrial Fibrillation:


edema, chest pain, angina pectoris

MGI Mouse Phenotypes related to Familial Atrial Fibrillation:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.17 GATA4 GATA5 GATA6 GJA5 KCNA5 KCNJ2
2 homeostasis/metabolism MP:0005376 9.97 GATA4 GATA5 GATA6 GJA5 KCNA5 KCNE2
3 digestive/alimentary MP:0005381 9.86 GATA4 GATA5 GJA5 KCNE2 KCNJ2 KCNQ1
4 muscle MP:0005369 9.73 GATA4 GATA5 GATA6 GJA5 KCNA5 KCNJ2
5 respiratory system MP:0005388 9.17 GATA4 GATA6 GJA5 KCNJ2 NKX2-5 PITX2
Sources

Drugs & Therapeutics for Familial Atrial Fibrillation

About this section

Drugs for Familial Atrial Fibrillation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 492)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
2
carbamide peroxide Approved Phase 4 124-43-6
3
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
4
Atorvastatin Approved Phase 4 134523-00-5 60823
5
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
6
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
7
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
8
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
9
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
10
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
11 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
12
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
13
Propranolol Approved, Investigational Phase 4 525-66-6 4946
14
Ezetimibe Approved Phase 4 163222-33-1 150311
15
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
16
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
17
Nifedipine Approved Phase 4 21829-25-4 4485
18
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
19
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
20
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
21
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
22
Phenindione Approved, Investigational Phase 4 83-12-5 4760
23 fluindione Approved, Investigational Phase 4 957-56-2
24
Ramipril Approved Phase 4 87333-19-5 5362129
25
Histamine Approved, Investigational Phase 4 51-45-6 774
26
Antazoline Approved Phase 4 91-75-8 2200
27
Terazosin Approved Phase 4 63590-64-7 5401
28
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
29
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
30
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
31
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
32
Pantoprazole Approved Phase 4 102625-70-7 4679
33
Dipyridamole Approved Phase 4 58-32-2 3108
34
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
35
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
36
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
37
AT-101 Approved, Investigational Phase 4 652-67-5, 90141-22-3 12597
38
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
39
Zinc Approved, Investigational Phase 4 7440-66-6 32051
40
Nitric Oxide Approved Phase 4 10102-43-9 145068
41
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
42
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
43 Bemiparin Approved, Investigational Phase 4 91449-79-5
44
Cefpirome Approved Phase 4 84957-29-9 5479539
45
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
46
Chlorothiazide Approved, Vet_approved Phase 4 58-94-6 2720
47
Metolazone Approved Phase 4 17560-51-9 4170
48
Tolvaptan Approved Phase 4 150683-30-0 216237
49
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
50
Polyestradiol phosphate Approved Phase 4 28014-46-2

Interventional clinical trials:

(show top 50) (show all 2960)
# Name Status NCT ID Phase Drugs
1 Rate Control in Atrial Fibrillation: A Randomized, Double-Blind, Crossover Comparison of Carvedilol and Metoprolol Tartrate Unknown status NCT02251509 Phase 4 Carvedilol;Metoprolol tartrate
2 Intensive Statin Therapy Effect on Incidence of Post-Operative Atrial Fibrillation Unknown status NCT02029534 Phase 4 Atorvastatin 20 mg;Atorvastatin 80 mg
3 Low Dose of Diltiazem for Rate Control of Atrial Fibrillation Unknown status NCT00834925 Phase 4 low dose diltiazem
4 A Prospective, Multi-Center, Pilot Study to Compare the Safety and Effectiveness of WATCHMAN Left Atrial Appendage Occlusion Device With Rivaroxaban for Stroke Prevention in Patients With Atrial Fibrillation Unknown status NCT02549963 Phase 4 Rivaroxaban
5 The Efficacy and Safety of Dabigatran Etexilate and Different Intensity Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation Unknown status NCT02646267 Phase 4 standard intensity warfarin;low intensity warfarin;dabigatran etexilate
6 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer: A Controlled, Randomized, Double Blinded Trial Unknown status NCT00724581 Phase 4 Amiodarone
7 Linear Anatomically Versus Focal Electrophysiologically Guided Substrate Ablation in Patients With Persistent Atrial Fibrillation Unknown status NCT00196157 Phase 4
8 Comparison of Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran in Patients With Non-valvular Atrial Fibrillation (RIVAL-AF Study) -Multicenter Randomized Study- Unknown status NCT02331602 Phase 4 Rivaroxaban;Dabigatran
9 N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure Unknown status NCT00692718 Phase 4 Epadel, Eicosapentaenoic acid
10 Catheter Ablation for Atrial Fibrillation: A Multicenter Clinical Trial Unknown status NCT01113294 Phase 4
11 Randomized Study Comparing Cardioversion vs. Catheter Ablation in Patients With Persistent Atrial Fibrillation Unknown status NCT00196209 Phase 4
12 Effects of Vernakalant and Flecainide on Atrial Contractility in Patients With Atrial Fibrillation Unknown status NCT01646281 Phase 4 Vernakalant;Flecainide
13 Left Atrial Ablation of Paroxysmal Atrial Fibrillation With Implantable Loop Recorder Follow Up Study 2 Unknown status NCT01504451 Phase 4
14 Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation Unknown status NCT02145546 Phase 4 Amiodarone;Propafenone;Sotalol
15 Phase â…£ Study of CARTO 3D Mapping System vs Conventional Method in AF & VT Unknown status NCT00959205 Phase 4
16 Additional Linear Ablation Perpendicular to the Pulmonary Vein Isolation Line Reduces the Recurrence Rate of Paroxysmal Atrial Fibrillation (ALA-PAF) Unknown status NCT02637453 Phase 4
17 Atrial Fibrillation Therapy: A Multi-Center Clinical Study Unknown status NCT01341353 Phase 4 Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists
18 A Nationwide Multicenter Trial Assessing the Effects of Catheter Ablation on Burden of Atrial Fibrillation Recorded by Implantable Cardiac Monitor Unknown status NCT02639793 Phase 4
19 PV-Isolation for Paroxysmal Atrial Fibrillation: Isolation of the Arrhythmogenic Vein(s) vs. Isolation of All Veins Unknown status NCT00605748 Phase 4
20 The Study of Rosuvastatin for Reduction of Postoperative Paroxysmal Atrial Fibrillation in Patient Undergoing Radiofrequency Catheter Ablation Unknown status NCT02502110 Phase 4 rosuvastatin
21 The Use of Dabigatran Etexilate in Patients With Atrial Fibrillation After Mitral Valve Prosthetic Replacement Unknown status NCT03183843 Phase 4 Dabigatran Etexilate;Warfarin
22 Improving Stroke Prevention in Atrial Fibrillation Through Pharmacist Prescribing: Program for the Identification of 'Actionable' AF (PIAAF) Rx Study Unknown status NCT03126214 Phase 4 Anticoagulants
23 Test of Efficacy and Safety of the Dual Antiplatelet Therapy Compared to the Combination of Oral Anticoagulant Therapy + Dual Antiplatelet Therapy in Patients With Atrial Fibrillation With Low-moderate Risk Submitted to Coronary Stent Implantation Unknown status NCT01141153 Phase 4 Acetylsalicylic Acid + clopidogrel + acenocoumarol;Acetylsalicylic Acid + clopidogrel
24 Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Unknown status NCT00224341 Phase 4
25 Left Atrial Ablation for Paroxysmal Atrial Fibrillation and Hypertension With Implantable Loop Recorder With or Without ROX Coupler Follow Up Study: The LAAPITUP 3 Study Unknown status NCT02243891 Phase 4
26 Randomized Controlled Trial to Evaluate Implanted Event Recorders for the First Diagnosis of Atrial Fibrillation in High-risk Patients Unknown status NCT01461434 Phase 4
27 Efficacy and Safety of Non-vitamin K Oral Anticoagulants and Vitamin K Oral Anticoagulants on Some Metabolic and Coagulation Parameters in Diabetic and Nondiabetic Patients With First Diagnosis of Non-valvular Atrial Fibrillation Unknown status NCT02935855 Phase 4 Dabigatran;Apixaban;Rivaroxaban;Edoxaban;Warfarin;Acenocumarole
28 Safety and Efficacy of Transvenous Pulmonary Isolation for the Treatment of Atrial Fibrillation: A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy Unknown status NCT00773539 Phase 4
29 Impact of Irbesartan on Oxidative Stress and C-Reactive Protein Levels in Patients With Persistent Atrial Fibrillation Unknown status NCT00613496 Phase 4 irbesartan;placebo
30 "Bidirectional Conduction Block of Left Atrial Anterior Line in Patients With Left Atrial Ablation - Reduction of RF Applications Using the Thermocool SmartTouch Contact Force Sensing Catheter Unknown status NCT02217657 Phase 4
31 Safety of Ticagrelor Plus Warfarin Versus Clopidogrel+Aspirin+Warfarin in Patients With Persistent or Permanent Atrial Fibrillation and Undergoing PCI-S: A Randomized, Open, Controlled, Parallel Group, Multi-center Trial Unknown status NCT02206815 Phase 4 Ticagrelor+Warfarin;Clopidogrel+Aspirin+Warfarin
32 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
33 A Prospective Study of Medical Therapy Against Cryoballoon Ablation in Symptomatic Recent Onset Persistent Atrial Fibrilation Unknown status NCT02389218 Phase 4 sequential drug adjustment (propafenone, sotalol or flecainide)
34 A Randomized, Prospective Multicenter Study to Determine the Incidence of Atrial Fibrillation and Heart Failure in Correlation to Stimulation Modes of Pacemakers Unknown status NCT00161551 Phase 4
35 Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Recurrent Atrial Fibrillation: A Prospective 2-Centre Randomized Controlled Clinical Study (POWDER-AF) Unknown status NCT02475642 Phase 4
36 APixaban Versus PhenpRocoumon: Oral AntiCoagulation Plus Antiplatelet tHerapy in Patients With Acute Coronary Syndrome and Atrial Fibrillation Unknown status NCT02789917 Phase 4
37 A Randomized, Prospective Multicenter Pilot Study to Determine the Influence of the Ventricular Pacing Site on the Incidence of Atrial Fibrillation and Heart Failure in Patients With Indication for Permanent Pacemaker Stimulation Therapy. Unknown status NCT00292383 Phase 4
38 AMIOCAAF (AMIOdarone vs. Catheter Ablation for Prevention of Recurrent Symptomatic Atrial Fibrillation): a Randomized Controlled Trial - Vanguard Phase Unknown status NCT02341105 Phase 4 Amiodarone
39 Dronedarone in Pacemaker Patients With Paroxysmal Atrial Fibrillation Unknown status NCT01070667 Phase 4 Dronedarone;Placebo
40 Atrial Fibrillation and Pericardial Drainage: Incidence of Postoperative Atrial Fibrillation According to the Type of Mediastinal Drainage Catheters Unknown status NCT02808897 Phase 4
41 EvaluAtion of Predictive Value of Multisite Intracardiac EchoCardiography During Imaging of Structure and funCTION of Left Atrial Appendage in Comparison to Transesophageal Echocardiography Unknown status NCT01371279 Phase 4
42 COR HF - Clinical Benefits in Optimized Remote HF Patient Management Unknown status NCT01482598 Phase 4
43 Comparison of Efficacy and Safety Among DAbigatran, RIvaroxaban, and ApixabaN in Patients HavinG Non-Valvular Atrial Fibrillation in Taiwan (DARING-AF Study) Unknown status NCT02666157 Phase 4 Dabigatran etexilate;Rivaroxaban;Apixaban
44 Comparison of a Rhythm Control Treatment Strategy Versus a Rate Control Strategy in Patients With Permanent or Long-term Persistent Atrial Fibrillation and Heart Failure Treated With Cardiac Resynchronization Therapy - a Pilot Study Unknown status NCT01850277 Phase 4 Amiodarone;Pharmacotherapy to slow and control ventricular rate
45 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study) Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
46 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
47 A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure Unknown status NCT03088072 Phase 4 Edoxaban;Aspirin and Clopidogrel;Aspirin and Warfarin
48 IntAct, Study on Promotion of Intrinsic Activity. Unknown status NCT00156741 Phase 4
49 Phenprocoumon Versus Dabigatran in Subjects With Atrial Fibrillation and Left Atrial Thrombus - a Prospective, Randomized, Controlled, Open-label One Year Follow-up Pilot Study Unknown status NCT02591225 Phase 4 Dabigatranetexilate;Phenprocoumon
50 Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Recently Diagnosed Impaired Left Ventricular Function: a Multicenter, Randomized Controlled Trial Unknown status NCT02509754 Phase 4

Search NIH Clinical Center for Familial Atrial Fibrillation

Inferred drug relations via UMLS 71 / NDF-RT 50 :


anisindione
Atenolol
Deslanoside
Digitalis preparation
DIGITALIS,POWDERED
Digitoxin
Digoxin
Diltiazem
Diltiazem Hydrochloride
Diltiazem maleate
Disopyramide
Disopyramide Phosphate
DITIAZ
dofetilide
ibutilide
ibutilide fumarate
Metoprolol
metoprolol succinate
Metoprolol Tartrate
Procainamide
Procainamide Hydrochloride
Propafenone
Propafenone Hydrochloride
Quinidine
quinidine gluconate
quinidine polygalacturonate
Quinidine Sulfate
Sotalol
Sotalol Hydrochloride
Verapamil
Verapamil hydrochloride
Warfarin
Warfarin Sodium
WARFARIN SODIUM ISOPROPANOL COMPLEX
Sources

Genetic Tests for Familial Atrial Fibrillation

About this section

Genetic tests related to Familial Atrial Fibrillation:

# Genetic test Affiliating Genes
1 Familial Atrial Fibrillation 29
Sources

Anatomical Context for Familial Atrial Fibrillation

About this section

MalaCards organs/tissues related to Familial Atrial Fibrillation:

40
Heart, Testes, Brain, Kidney, Lung, Endothelial, Liver
Sources

Publications for Familial Atrial Fibrillation

About this section

Articles related to Familial Atrial Fibrillation:

(show top 50) (show all 105)
# Title Authors PMID Year
1
A novel SCN5A gain-of-function mutation M1875T associated with familial atrial fibrillation. 61 54
18929244 2008
2
Cardiac sodium channel mutation in atrial fibrillation. 61 54
18088563 2008
3
Human KCNQ1 S140G mutation is associated with atrioventricular blocks. 61 54
17467630 2007
4
Atrial fibrillation in KCNE1-null mice. 61 54
15947250 2005
5
Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation. 54 61
15368194 2004
6
KCNQ1 gain-of-function mutation in familial atrial fibrillation. 54 61
12522251 2003
7
Clinical profile and outcome of familial versus non-familial atrial fibrillation. 61
32273045 2020
8
The Genetic Puzzle of Familial Atrial Fibrillation. 61
32118049 2020
9
Putative role of Brugada syndrome genes in familial atrial fibrillation. 61
31539150 2019
10
Electrophysiologic and molecular mechanisms of a frameshift NPPA mutation linked with familial atrial fibrillation. 61
31077706 2019
11
Characterization and haplotype study of 6 novel STR markers related to the KCNQ1 gene in heterogeneous cardiovascular disorders in the Iranian population 61
30866607 2019
12
A Novel PITX2c Gain-of-Function Mutation, p.Met207Val, in Patients With Familial Atrial Fibrillation. 61
30558760 2019
13
Proarrhythmia in the p.Met207Val PITX2c-Linked Familial Atrial Fibrillation-Insights From Modeling. 61
31695623 2019
14
Molecular Insights into the Short QT Syndrome. 61
31355049 2018
15
A SHOX2 loss-of-function mutation underlying familial atrial fibrillation. 61
30443179 2018
16
Familial clustering of atrial fibrillation and comparative longitudinal outcomes of familial and non-familial atrial fibrillation. 61
28485191 2017
17
Generation and cardiac subtype-specific differentiation of PITX2-deficient human iPS cell lines for exploring familial atrial fibrillation. 61
28677534 2017
18
A frameshift deletion in the sarcomere gene MYL4 causes early-onset familial atrial fibrillation. 61
27742809 2017
19
Prognosis in Familial Atrial Fibrillation. 61
27866163 2016
20
Outcomes Associated With Familial Versus Nonfamilial Atrial Fibrillation: A Matched Nationwide Cohort Study. 61
27866162 2016
21
A novel nonsense mutation in LMNA gene identified by Exome Sequencing in an atrial fibrillation family. 61
27373676 2016
22
Cardiac Delayed Rectifier Potassium Channels in Health and Disease. 61
27261823 2016
23
Clinical Features of Genetic Cardiac Diseases Related to Potassium Channelopathies. 61
27261827 2016
24
A mutation in the atrial-specific myosin light chain gene (MYL4) causes familial atrial fibrillation. 61
27066836 2016
25
Examining rare and low-frequency genetic variants previously associated with lone or familial forms of atrial fibrillation in an electronic medical record system: a cautionary note. 61
25410959 2015
26
NKX2-6 mutation predisposes to familial atrial fibrillation. 61
25319568 2014
27
TNNI3K mutation in familial syndrome of conduction system disease, atrial tachyarrhythmia and dilated cardiomyopathy. 61
24925317 2014
28
Whole-exome sequencing in familial atrial fibrillation. 61
24727801 2014
29
KCNE2 modulates cardiac L-type Ca(2+) channel. 61
24681347 2014
30
Gremlin 2 promotes differentiation of embryonic stem cells to atrial fate by activation of the JNK signaling pathway. 61
24648383 2014
31
In silico investigation of a KCNQ1 mutation associated with familial atrial fibrillation. 61
24411289 2014
32
Pitx2, an atrial fibrillation predisposition gene, directly regulates ion transport and intercalated disc genes. 61
24395921 2014
33
A novel PITX2c loss-of-function mutation associated with familial atrial fibrillation. 61
24333117 2014
34
Selective targeting of gain-of-function KCNQ1 mutations predisposing to atrial fibrillation. 61
24006450 2013
35
Prevalence and spectrum of PITX2c mutations associated with familial atrial fibrillation. 61
23611745 2013
36
Characteristics of atrial fibrillation and comorbidities in familial atrial fibrillation. 61
23551519 2013
37
Mutations of the SCN4B-encoded sodium channel β4 subunit in familial atrial fibrillation. 61
23604097 2013
38
A KCNQ1 mutation causes a high penetrance for familial atrial fibrillation. 61
23350853 2013
39
A novel NKX2.5 loss-of-function mutation responsible for familial atrial fibrillation. 61
23525379 2013
40
A heterozygous variant in the human cardiac miR-133 gene, MIR133A2, alters miRNA duplex processing and strand abundance. 61
23497314 2013
41
Familial atrial fibrillation predicts increased risk of mortality: a study in Danish twins. 61
23255276 2013
42
[KCNQ1 mutation in patients with lone atrial fibrillation]. 61
23651960 2013
43
Polymorphisms but not mutations of the KCNQ1 gene are associated with lone atrial fibrillation in the Chinese Han population. 61
23710137 2013
44
Novel GATA5 loss-of-function mutations underlie familial atrial fibrillation. 61
23295592 2012
45
Novel GATA6 loss-of-function mutation responsible for familial atrial fibrillation. 61
22824924 2012
46
Pro-arrhythmogenic effects of the S140G KCNQ1 mutation in human atrial fibrillation - insights from modelling. 61
22508963 2012
47
Chromosome 4q25 variants are genetic modifiers of rare ion channel mutations associated with familial atrial fibrillation. 61
22818067 2012
48
Mutational spectrum of the GATA5 gene associated with familial atrial fibrillation. 61
22483626 2012
49
Mutations in the potassium channel subunit KCNE1 are associated with early-onset familial atrial fibrillation. 61
22471742 2012
50
The role of atrial natriuretic peptide in modulating cardiac electrophysiology. 61
22083030 2012
Sources

Variations for Familial Atrial Fibrillation

About this section

ClinVar genetic disease variations for Familial Atrial Fibrillation:

6 (show top 50) (show all 100) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MYL4 NM_002476.2(MYL4):c.31G>A (p.Glu11Lys)SNV Pathogenic 224067 rs886037778 17:45286819-45286819 17:47209453-47209453
2 KCNJ2 NM_000891.2(KCNJ2):c.1259C>T (p.Pro420Leu)SNV Conflicting interpretations of pathogenicity 264482 rs749707062 17:68172439-68172439 17:70176298-70176298
3 KCNQ1 NM_181798.1(KCNQ1):c.808C>T (p.Arg270Trp)SNV Conflicting interpretations of pathogenicity 52970 rs199472776 11:2608860-2608860 11:2587630-2587630
4 ABCC9 NM_005691.3(ABCC9):c.2770-13A>GSNV Conflicting interpretations of pathogenicity 162686 rs184123387 12:22001193-22001193 12:21848259-21848259
5 ABCC9 NM_005691.3(ABCC9):c.2199-6T>CSNV Conflicting interpretations of pathogenicity 180001 rs535477725 12:22017417-22017417 12:21864483-21864483
6 ABCC9 NM_005691.3(ABCC9):c.2826T>C (p.Tyr942=)SNV Conflicting interpretations of pathogenicity 201611 rs141025897 12:22001124-22001124 12:21848190-21848190
7 KCNQ1 NM_181798.1(KCNQ1):c.1133+3G>ASNV Conflicting interpretations of pathogenicity 304226 rs374767819 11:2683314-2683314 11:2662084-2662084
8 LAMA4 NM_001105206.3(LAMA4):c.3742A>G (p.Ile1248Val)SNV Conflicting interpretations of pathogenicity 488160 rs547323858 6:112454047-112454047 6:112132845-112132845
9 ABCC9 NM_005691.3(ABCC9):c.-11T>CSNV Conflicting interpretations of pathogenicity 35625 rs72559432 12:22089619-22089619 12:21936685-21936685
10 ABCC9 NM_005691.3(ABCC9):c.2644-11G>ASNV Conflicting interpretations of pathogenicity 35631 rs61926078 12:22005167-22005167 12:21852233-21852233
11 ABCC9 NM_005691.3(ABCC9):c.1165-19dupduplication Conflicting interpretations of pathogenicity 45385 rs35857705 12:22063251-22063252 12:21910317-21910318
12 ABCC9 NM_020297.3(ABCC9):c.1557G>A (p.Glu519=)SNV Conflicting interpretations of pathogenicity 45388 rs143346402 12:22059121-22059121 12:21906187-21906187
13 ABCC9 NM_020297.3(ABCC9):c.2862C>T (p.Asp954=)SNV Conflicting interpretations of pathogenicity 45407 rs2291550 12:22001088-22001088 12:21848154-21848154
14 ABCC9 NM_020297.3(ABCC9):c.372T>C (p.Asn124=)SNV Conflicting interpretations of pathogenicity 45410 rs377384557 12:22078910-22078910 12:21925976-21925976
15 ABCC9 NM_005691.3(ABCC9):c.407-14C>ASNV Conflicting interpretations of pathogenicity 45412 rs201279882 12:22070051-22070051 12:21917117-21917117
16 KCNQ1 NM_181798.1(KCNQ1):c.870+13C>TSNV Conflicting interpretations of pathogenicity 304220 rs201364493 11:2608935-2608935 11:2587705-2587705
17 ABCC9 NM_005691.3(ABCC9):c.1332C>T (p.Gly444=)SNV Conflicting interpretations of pathogenicity 308041 rs369830406 12:22061134-22061134 12:21908200-21908200
18 ABCC9 NM_005691.3(ABCC9):c.1659+10T>CSNV Conflicting interpretations of pathogenicity 308040 rs201753781 12:22048199-22048199 12:21895265-21895265
19 ABCC9 NM_005691.3(ABCC9):c.1165-7_1165-6deldeletion Conflicting interpretations of pathogenicity 308043 rs35857705 12:22063252-22063253 12:21910318-21910319
20 ABCC9 NM_005691.3(ABCC9):c.669G>T (p.Leu223=)SNV Uncertain significance 308045 rs17846788 12:22068749-22068749 12:21915815-21915815
21 ABCC9 NM_005691.3(ABCC9):c.146G>C (p.Trp49Ser)SNV Uncertain significance 308048 rs886049175 12:22086854-22086854 12:21933920-21933920
22 ABCC9 NM_005691.3(ABCC9):c.3669+10T>CSNV Uncertain significance 308033 rs199640712 12:21981882-21981882 12:21828948-21828948
23 ABCC9 NM_005691.3(ABCC9):c.466T>C (p.Cys156Arg)SNV Uncertain significance 308046 rs886049173 12:22069978-22069978 12:21917044-21917044
24 KCNJ2 NM_000891.2(KCNJ2):c.-88C>TSNV Uncertain significance 324828 rs886053322 17:68171093-68171093 17:70174952-70174952
25 KCNJ2 NM_000891.2(KCNJ2):c.*1702_*1704dupduplication Uncertain significance 324862 rs1555604193 17:68174165-68174166 17:70178024-70178025
26 KCNJ2 NM_000891.2(KCNJ2):c.*1720_*1721dupduplication Uncertain significance 324866 rs35753731 17:68174168-68174169 17:70178027-70178028
27 KCNJ2 NM_000891.2(KCNJ2):c.*1721dupduplication Uncertain significance 324865 rs35753731 17:68174168-68174169 17:70178027-70178028
28 KCNJ2 NM_000891.2(KCNJ2):c.*1719_*1721dupduplication Uncertain significance 324867 rs35753731 17:68174168-68174169 17:70178027-70178028
29 KCNJ2 NM_000891.2(KCNJ2):c.*2774_*2775deldeletion Uncertain significance 324880 rs35656864 17:68175206-68175207 17:70179065-70179066
30 KCNJ2 NM_000891.2(KCNJ2):c.*2775dupduplication Uncertain significance 324879 rs35656864 17:68175205-68175206 17:70179064-70179065
31 KCNJ2 NM_000891.2(KCNJ2):c.*2776deldeletion Uncertain significance 324885 rs886053343 17:68175240-68175240 17:70179099-70179099
32 KCNJ2 NM_000891.2(KCNJ2):c.*1702dupduplication Uncertain significance 324863 rs886053334 17:68174165-68174166 17:70178024-70178025
33 KCNJ2 NM_000891.2(KCNJ2):c.*2771_*2775deldeletion Uncertain significance 324882 rs35656864 17:68175206-68175210 17:70179065-70179069
34 KCNJ2 NM_000891.2(KCNJ2):c.*2772_*2775deldeletion Uncertain significance 324881 rs35656864 17:68175206-68175209 17:70179065-70179068
35 KCNE2 NM_172201.1(KCNE2):c.-121C>TSNV Uncertain significance 339713 rs188625398 21:35736342-35736342 21:34364043-34364043
36 KCNQ1 NM_181798.1(KCNQ1):c.*897G>TSNV Uncertain significance 304266 rs561861522 11:2870130-2870130 11:2848900-2848900
37 ABCC9 NM_005691.3(ABCC9):c.3556C>T (p.Arg1186Trp)SNV Uncertain significance 308034 rs886049169 12:21991022-21991022 12:21838088-21838088
38 ABCC9 NM_005691.3(ABCC9):c.1165-4deldeletion Uncertain significance 308042 rs886049172 12:22063250-22063250 12:21910316-21910316
39 ABCC9 NM_005691.3(ABCC9):c.842G>A (p.Arg281Gln)SNV Uncertain significance 308044 rs753456211 12:22065975-22065975 12:21913041-21913041
40 ABCC9 NM_005691.3(ABCC9):c.366T>C (p.Tyr122=)SNV Uncertain significance 308047 rs886049174 12:22078916-22078916 12:21925982-21925982
41 ABCC9 NM_005691.3(ABCC9):c.75T>C (p.Phe25=)SNV Uncertain significance 308049 rs201972673 12:22089534-22089534 12:21936600-21936600
42 KCNQ1 NM_000218.2(KCNQ1):c.29C>A (p.Ala10Asp)SNV Uncertain significance 304214 rs886048161 11:2466357-2466357 11:2445127-2445127
43 KCNQ1 NM_000218.2(KCNQ1):c.66C>T (p.Gly22=)SNV Uncertain significance 304215 rs886048162 11:2466394-2466394 11:2445164-2445164
44 KCNQ1 NM_181798.1(KCNQ1):c.400-6G>TSNV Uncertain significance 304218 rs886048164 11:2594070-2594070 11:2572840-2572840
45 KCNQ1 NM_181798.1(KCNQ1):c.*398C>TSNV Uncertain significance 304246 rs886048170 11:2869631-2869631 11:2848401-2848401
46 ABCC9 NM_005691.3(ABCC9):c.4316-14T>GSNV Uncertain significance 308032 rs886049168 12:21960427-21960427 12:21807493-21807493
47 ABCC9 NM_005691.3(ABCC9):c.2769+12T>CSNV Uncertain significance 308035 rs564071879 12:22005019-22005019 12:21852085-21852085
48 ABCC9 NM_005691.3(ABCC9):c.2238-16deldeletion Uncertain significance 308036 rs886049170 12:22016004-22016004 12:21863070-21863070
49 ABCC9 NM_005691.3(ABCC9):c.1992C>T (p.Pro664=)SNV Uncertain significance 308038 rs780071007 12:22035727-22035727 12:21882793-21882793
50 ABCC9 NM_005691.3(ABCC9):c.1670C>G (p.Thr557Ser)SNV Uncertain significance 308039 rs886049171 12:22047098-22047098 12:21894164-21894164
Sources

Expression for Familial Atrial Fibrillation

About this section
Search GEO for disease gene expression data for Familial Atrial Fibrillation.
Sources

Pathways for Familial Atrial Fibrillation

About this section

Pathways related to Familial Atrial Fibrillation according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Cardiac conduction 65
Show member pathways
 12.42 SCN5A SCN4B SCN3B SCN2B NPPA NKX2-5
2
cGMP-PKG signaling pathway 36
Show member pathways
 12.38 SCN5A SCN4B NPPA MYL4 KCNQ1 GATA4
3
Dopamine-DARPP32 Feedback onto cAMP Pathway 63
12.17 KCNQ1 KCNJ2 KCNE2 KCNA5
4
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.99 SCN5A SCN4B SCN3B KCNQ1
5
L1CAM interactions 65
Show member pathways
 11.85 SCN5A SCN4B SCN3B SCN2B
6
Phase 0 - rapid depolarisation 65
Show member pathways
 11.51 SCN5A SCN4B SCN3B SCN2B KCNQ1 KCNE2
7
Cardiac Progenitor Differentiation 1
11.4 SCN5A NKX2-5 GATA4
8
Transcriptional Regulatory Network in Embryonic Stem Cell 63
11.34 MYL4 GATA6 GATA4
9
Heart Development 1
11.33 PITX2 NKX2-5 GATA6 GATA4
10
Interaction between L1 and Ankyrins 65
11.03 SCN5A SCN4B SCN3B SCN2B
11
Antiarrhythmic Pathway, Pharmacodynamics 60
11.02 SCN5A SCN4B SCN3B SCN2B KCNQ1 KCNJ2
12
Cardiomyocyte Differentiation through BMP Receptors 63
10.95 NPPA NKX2-5 GATA4
13
TarBasePathway 1
10.8 KCNQ1 KCNJ2
14
HOP Signaling 63
10.28 NPPA NKX2-5 GATA4
Sources

GO Terms for Familial Atrial Fibrillation

About this section

Cellular components related to Familial Atrial Fibrillation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 voltage-gated potassium channel complex GO:0008076 9.46 KCNQ1 KCNJ2 KCNE2 KCNA5
2 Z disc GO:0030018 9.43 SCN5A SCN3B KCNA5
3 voltage-gated sodium channel complex GO:0001518 9.26 SCN5A SCN4B SCN3B SCN2B
4 intercalated disc GO:0014704 9.02 SCN5A SCN4B KCNJ2 KCNA5 GJA5

Biological processes related to Familial Atrial Fibrillation according to GeneCards Suite gene sharing:

(show all 48)
# Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 10.16 SCN5A SCN4B SCN3B SCN2B KCNQ1 KCNJ2
2 potassium ion transport GO:0006813 9.99 KCNQ1 KCNJ2 KCNE2 KCNA5 GJA5
3 potassium ion transmembrane transport GO:0071805 9.95 KCNQ1 KCNJ2 KCNE2 KCNA5
4 sodium ion transport GO:0006814 9.95 SCN5A SCN4B SCN3B SCN2B
5 sodium ion transmembrane transport GO:0035725 9.93 SCN5A SCN4B SCN3B SCN2B
6 regulation of ion transmembrane transport GO:0034765 9.92 SCN5A SCN4B SCN3B SCN2B KCNQ1 KCNJ2
7 cardiac conduction GO:0061337 9.88 SCN5A SCN3B KCNQ1 KCNJ2 KCNE2 GJA5
8 regulation of ventricular cardiac muscle cell membrane repolarization GO:0060307 9.85 SCN5A SCN4B KCNQ1 KCNE2 GJA5
9 cell fate commitment GO:0045165 9.84 GATA6 GATA5 GATA4
10 cardiac muscle tissue development GO:0048738 9.83 NKX2-5 GATA6 GATA5 GATA4
11 ventricular cardiac muscle cell action potential GO:0086005 9.83 SCN5A SCN3B KCNQ1 KCNE2 GJA5
12 cardiac muscle cell differentiation GO:0055007 9.81 NKX2-5 GATA6 GATA4
13 positive regulation of heart rate GO:0010460 9.81 SCN3B NPPA KCNQ1
14 positive regulation of sodium ion transport GO:0010765 9.81 SCN5A SCN4B SCN3B NKX2-5
15 regulation of sodium ion transmembrane transporter activity GO:2000649 9.8 SCN4B SCN3B SCN2B
16 regulation of atrial cardiac muscle cell membrane depolarization GO:0060371 9.8 SCN5A SCN3B SCN2B GJA5
17 potassium ion export across plasma membrane GO:0097623 9.79 KCNQ1 KCNE2 KCNA5
18 regulation of cardiac muscle cell contraction GO:0086004 9.79 SCN5A KCNJ2 GATA4
19 atrial septum morphogenesis GO:0060413 9.78 NKX2-5 GJA5 GATA4
20 regulation of atrial cardiac muscle cell membrane repolarization GO:0060372 9.78 SCN5A NPPA KCNQ1 KCNA5
21 regulation of membrane repolarization GO:0060306 9.77 KCNQ1 KCNJ2 KCNE2
22 membrane depolarization during cardiac muscle cell action potential GO:0086012 9.77 SCN5A SCN4B SCN3B SCN2B KCNJ2
23 membrane repolarization during action potential GO:0086011 9.76 KCNQ1 KCNJ2 KCNE2
24 intestinal epithelial cell differentiation GO:0060575 9.75 GATA6 GATA5 GATA4
25 regulation of ventricular cardiac muscle cell membrane depolarization GO:0060373 9.74 SCN5A SCN3B GJA5
26 SA node cell action potential GO:0086015 9.72 SCN5A SCN3B GJA5
27 positive regulation of cardioblast differentiation GO:0051891 9.71 NKX2-5 GATA6 GATA4
28 regulation of cardiac muscle contraction GO:0055117 9.7 NKX2-5 GJA5
29 membrane depolarization GO:0051899 9.7 SCN5A SCN3B
30 embryonic heart tube development GO:0035050 9.7 NKX2-5 GJA5
31 membrane depolarization during action potential GO:0086010 9.7 SCN5A SCN3B
32 cardiac muscle contraction GO:0060048 9.7 SCN5A SCN4B SCN3B SCN2B NKX2-5 MYL4
33 cardiovascular system development GO:0072358 9.69 NKX2-5 KCNQ1
34 cell growth involved in cardiac muscle cell development GO:0061049 9.69 NPPA GATA4
35 positive regulation of potassium ion transmembrane transport GO:1901381 9.69 KCNQ1 KCNJ2
36 cardiac muscle hypertrophy in response to stress GO:0014898 9.68 NPPA GATA6
37 membrane repolarization during ventricular cardiac muscle cell action potential GO:0098915 9.68 KCNQ1 KCNE2
38 membrane repolarization GO:0086009 9.68 KCNQ1 KCNE2
39 positive regulation of cardiac muscle contraction GO:0060452 9.68 NPPA KCNQ1
40 membrane repolarization during cardiac muscle cell action potential GO:0086013 9.67 KCNQ1 KCNJ2
41 cardiac ventricle morphogenesis GO:0003208 9.67 NKX2-5 GATA4
42 membrane repolarization during atrial cardiac muscle cell action potential GO:0098914 9.66 KCNQ1 KCNA5
43 cardiac conduction system development GO:0003161 9.66 NKX2-5 GJA5
44 AV node cell action potential GO:0086016 9.65 SCN5A SCN4B
45